| scholarly article | Q13442814 |
| P50 | author | Chris Twelves | Q47067174 |
| Jeffrey A Meyerhardt | Q89850327 | ||
| Nadine Jackson McCleary | Q92628336 | ||
| Eric Van Cutsem | Q37068027 | ||
| Leonard B. Saltz | Q37830465 | ||
| Aimery de Gramont | Q38294926 | ||
| P2093 | author name string | Daniel J Sargent | |
| Greg Yothers | |||
| Daniel G Haller | |||
| Erin Green | |||
| Michael O'Connell | |||
| P2860 | cites work | Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial | Q46750806 |
| Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. | Q51960759 | ||
| Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. | Q53247090 | ||
| Body mass index and mortality among older people living in the community | Q53792771 | ||
| Co-morbidity and functional deficits independently contribute to quality of life before chemotherapy in elderly cancer patients | Q79822187 | ||
| Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803 | Q80768425 | ||
| Global cancer statistics | Q22241238 | ||
| Cancer statistics, 2010 | Q27860525 | ||
| Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer | Q33372496 | ||
| Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. | Q33839100 | ||
| Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group | Q34057488 | ||
| Capecitabine as adjuvant treatment for stage III colon cancer | Q34429990 | ||
| Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. | Q34579124 | ||
| Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial | Q34607843 | ||
| Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08 | Q34662825 | ||
| The predictive value of self assessed general, physical, and mental health on functional decline and mortality in older adults. | Q35401070 | ||
| Targeted agents for adjuvant therapy of colon cancer | Q36687650 | ||
| Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study | Q36760924 | ||
| Comprehensive geriatric assessment for older patients with cancer | Q36815525 | ||
| Colorectal cancer screening in elderly patients: when should be more useful? | Q36842151 | ||
| Relation between cognitive impairment and early death in the elderly | Q39897841 | ||
| Age, severe comorbidity and functional impairment independently contribute to poor survival in cancer patients | Q42513324 | ||
| A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients | Q43763447 | ||
| Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. | Q44919656 | ||
| Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials | Q45287822 | ||
| The effect of comorbidity on 3-year survival of women with primary breast cancer | Q46637774 | ||
| N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer | Q46730218 | ||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | database | Q8513 |
| patient | Q181600 | ||
| colon cancer | Q18555025 | ||
| P304 | page(s) | 2600-2606 | |
| P577 | publication date | 2013-06-03 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database | |
| P478 | volume | 31 |
| Q92624944 | Adjuvant chemotherapy does not provide survival benefits to elderly patients with stage II colon cancer |
| Q36429095 | Adjuvant chemotherapy for colon cancer: a consensus statement of the Hellenic and Cypriot Colorectal Cancer Study Group by the HeSMO. |
| Q93136708 | Adjuvant chemotherapy in stage II-III operated colon cancer patients from a nontrial cohort in a low colon cancer prevalence country with predominant use of modified CAPOX |
| Q34368278 | Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies |
| Q35817933 | Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum |
| Q35920292 | Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer--results from a non-interventional observation study. |
| Q37598467 | Challenges in the Management of Older Patients With Colon Cancer |
| Q35567604 | Chemotherapy for colorectal cancer in the elderly |
| Q35978879 | Chemotherapy use in stage III colon cancer: a National Cancer Database analysis |
| Q36473901 | Clinical Practice in the Use of Adjuvant Chemotherapy for Patients with Colon Cancer in South Korea: a Multi-Center, Prospective, Observational Study |
| Q47156783 | Clinicopathologic features and prognostic factors for patients with colorectal cancer who are 75 years and older. |
| Q89218269 | Colorectal cancer |
| Q33579145 | Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases |
| Q30422446 | Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer |
| Q36913615 | Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy |
| Q30422095 | Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis. |
| Q49826245 | Competing nomograms help in the selection of elderly patients with colon cancer for adjuvant chemotherapy. |
| Q38691264 | Controversies in the multimodality management of locally advanced rectal cancer |
| Q30244769 | Decision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer |
| Q38265049 | Determinants of recurrence after intended curative resection for colorectal cancer |
| Q38534405 | Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis |
| Q34656360 | Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. |
| Q50085723 | Effect of Adjuvant Chemotherapy on Elderly Colorectal Cancer Patients: Lack of Evidence |
| Q37133361 | Effectiveness of adjuvant chemotherapy for elderly patients with lymph node-positive colorectal cancer. |
| Q54878242 | Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colorectal cancer: the ACCORE study. |
| Q36154007 | Efficacy of surgery and adjuvant therapy in older patients with colorectal cancer: a STROBE-compliant article |
| Q92107890 | High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage III colon cancer after curative resection and adjuvant chemotherapy |
| Q47166784 | Identification of Key Genes in Colorectal Cancer Regulated by miR-34a. |
| Q30884763 | Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. |
| Q37190135 | Impact of age on efficacy of postoperative oxaliplatin-based chemotherapy in patients with rectal cancer after neoadjuvant chemoradiotherapy |
| Q64251306 | Impact of old age on resectable colorectal cancer outcomes |
| Q31119154 | Leveraging the power of pooled data for cancer outcomes research |
| Q35733020 | Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial |
| Q92716670 | Making sense of adjuvant chemotherapy in colorectal cancer |
| Q26823550 | Management of colorectal cancer |
| Q54959817 | Management of locally advanced rectal cancer in the elderly: a critical review and algorithm. |
| Q40271928 | Management of stage III colon cancer in the elderly: Practice patterns and outcomes in the general population. |
| Q30249616 | Optimizing adjuvant therapy and survivorship care of stage III colon cancer. |
| Q35779359 | Overall Survival of Stage III Colon Cancer with Only One Lymph Node Metastasis Is Independently Predicted by Preoperative Carcinoembryonic Antigen Level and Lymph Node Sampling Status. |
| Q36824126 | Patterns of Colorectal Cancer Care in the United States: 1990-2010. |
| Q37697526 | Personalized surgical management of colorectal cancer in elderly population |
| Q36954147 | Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer. |
| Q40586852 | Recurrence-free and overall survival among elderly stage III colon cancer patients treated with CAPOX or capecitabine monotherapy |
| Q34083135 | S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial). |
| Q37242523 | Safety and Effectiveness of Oxaliplatin-Based Chemotherapy Regimens in Adults 75 Years and Older With Colorectal Cancer |
| Q36851424 | Senior adult oncology |
| Q35780153 | Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70 |
| Q48143774 | The differences on efficacy of oxaliplatin in locally advanced colon cancer between mucinous and nonmucinous adenocarcinoma |
| Q33851067 | The effect of geriatric intervention in frail elderly patients receiving chemotherapy for colorectal cancer: a randomized trial (GERICO). |
| Q37698196 | To treat or not to treat: who should decide? |
| Q38228522 | Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. |
| Q26781457 | Treatment of colorectal cancer in the elderly |
| Q37704350 | Treatment of older patients with colorectal cancer: a perspective review |
| Q38920929 | Trends in colorectal cancer in the elderly in Denmark, 1980-2012. |
| Q55114129 | Use of adjuvant chemotherapy in patients with stage III colon cancer in Puerto Rico: A population-based study. |
| Q37507061 | Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database |
| Q50080163 | What is the optimal duration of adjuvant therapy in colon cancer? |
Search more.